286 results on '"Darreh-Shori, Taher"'
Search Results
2. Synthesis and biological evaluation of Halogen-Substituted novel α-Ketoamides as potential protein aggregation modulators in Alzheimer’s disease
3. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
4. Synthesis, single crystal X-ray, DFT, spectroscopic, molecular docking studies and in vitro biological evaluation of compound N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide
5. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
6. Cholinergic pathway modulation by age‐dependent amyloid‐beta pathology in an APP‐knock‐in AD mice model
7. Presence of key cholinergic enzymes in human spermatozoa and seminal fluid
8. Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions
9. Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer’s Disease Brain
10. Presence of key cholinergic enzymes in human spermatozoa and seminal fluid†
11. Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas
12. Mechanistic Insight into the Inhibition of Choline Acetyltransferase by Proton Pump Inhibitors
13. Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppNL−G−F knock-in Alzheimer mice.
14. O003 / #714 COGNITIVE RESTORATION IN ALZHEIMER’S PATIENTS BY LOCAL INTRACEREBRAL CELL-MEDIATED NERVE GROWTH FACTOR DELIVERY: CLINICAL EFFICACY AND FURTHER METHOD OPTIMIZATION
15. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia
16. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
17. Allosteric Binding Sites of Aβ Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling
18. Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects
19. FC081: Cholinesterase Inhibitors and Kidney Function Decline in Patients with Alzheimer's Dementia
20. Fast Alpha Activity in EEG of Patients With Alzheimer’s Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor
21. Fast Alpha Activity in EEG of Patients With Alzheimer's Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor
22. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
23. Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs
24. CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment
25. Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers
26. Fibrillar β-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation
27. Insulin-Independent and Dependent Glucose Transporters in Brain Mural Cells in CADASIL
28. Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index
29. Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET
30. Additional file 1 of Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions
31. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
32. Association of glial and neuronal degeneration markers with Alzheimer‘s disease cerebrospinal fluid profile and cognitive functions
33. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia
34. Influence of a genetic variant of CHAT gene over the profile of plasma soluble ChAT in Alzheimer disease
35. CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
36. Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
37. Additional file 1: of Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas
38. Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer’s Disease Status and Risk Genotype
39. O5‐06‐06: LIGANDS OF THE CORE ACETYLCHOLINE BIOSYNTHESIZING ENZYME, CHOLINE ACETYLTRANSFERASE, AS NOVEL AND POTENTIAL THERAPEUTIC AGENTS AND IN VIVO PET TRACERS FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE
40. P1-090: DISCOVERY OF NOVEL SMALL MOLECULES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
41. P2-109: CSF CHOLINERGIC INDEX, A NEW BIOMEASURE OF TREATMENT EFFECT IN PATIENTS WITH ALZHEIMER'S DISEASE
42. P3-108: CHAT POTENTIATING LIGANDS (CPLS): A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
43. Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer’s Disease Brain
44. Changes in neuromuscular structure and functions of human colon during ageing are region-dependent
45. Soluble Aβ42 Acts as Allosteric Activator of the Core Cholinergic Enzyme Choline Acetyltransferase
46. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
47. P1‐001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI
48. P3‐207: ARE VISUAL HALLUCINATIONS IN ALZHEIMER'S DISEASE A RESULT OF HYPOPERFUSION OF VISUAL PROCESSING AREAS IN THE OCCIPITAL CORTEX?
49. P1‐241: SOLUBLE AMYLOID‐BETA ACTIVATES CHOLINE ACETYLTRANSFERASE
50. Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.